7 February 2024
31 January 2024
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access through public reimbursement to BRUKINSA® (zanubrutinib)
30 October 2023
Helping Canadian Cancer Research & Innovation – BeiGene Canada’s Pioneering Fund
29 August 2023
Press Conference: Peter Brenders announces the launch of the BeiGene Canada Fund for Research and Innovation
22 August 2023
BeiGene Canada Invests 500K To Fund Innovative Cancer Research
30 May 2023
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adult
6 February 2023
Quebec becomes first province to cover BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s macroglobulinemia
9 January 2023
BeiGene Canada Named a Great Place to Work®
8 April 2021